SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: Cacaito who wrote (8286)1/14/1999 9:05:00 AM
From: Robert K.  Read Replies (2) | Respond to of 17367
 
Yes, I agree with the combination possibilites too on bpi21.
Phase 1 in a long ways off, isnt it.
Regarding the Ligand threat to hu1124, remember the p1/2 on hu1124 showed a result with just one dose. Also a threat is zenepax (roche). And that also presents thought as roche owns most of gne and has a defacto deal with xoma/hu1124.
All IMO.